^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TGFBeta resistant HER2/EBV-CTLs
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Baylor Scott & White Research Institute
Drug class:
HER2-targeted CAR-T immunotherapy
Related drugs:
Phase 1
Baylor College of Medicine
Completed
Last update posted :
09/18/2018
Initiation :
05/01/2009
Primary completion :
07/01/2015
Completion :
01/21/2018
HER-2
|
HER-2 positive • HER-2 negative • HER-2 expression
|
TGFBeta resistant HER2/EBV-CTLs
Share
